Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan unveils generic Mesnex Injection
The product is the generic equivalent to Baxter Healthcare’s Mesnex Injection. Mylan has begun shipping the generic drug, which has been approved by the US Food and Drug
The product is the generic equivalent to Baxter Healthcare’s Mesnex Injection. Mylan has begun shipping the generic drug, which has been approved by the US Food and Drug
Ingenuity iReport for Real-Time PCR provides a rapid and comprehensive understanding of pathways, processes, and diseases relevant to gene expression results. The new solution is an interactive report
AggregateSpend360 will support local, country-specific and global transparency and reporting requirements. The service, available in Software as a Service (SaaS) and licensed models, collects all necessary compliance data
The three patients of cohort 2 received a dose of 1×10(9) colony forming units (cfu)/day for up to 28 days of continuous oral dosing. Dosing of third cohort
Irbesartan and Irbesartan-Hydrochlorothiazide tablets are generic equivalents to Sanofi Aventis’ high blood pressure treatments, Avapro and Avalide tablets. Teva has been granted a 180-day period of marketing exclusivity,
Simponi solution for injection is a human TNFa monoclonal antibody, golimumab. Simponi was discovered and developed by Jansen Biotech as a treatment for inflammatory autoimmune diseases (involving TNFa)
The new unit has been supported by a £145,000 grant from Scottish Enterprise, reports inpharm.com. The Scottish deputy minister Nicola Sturgeon has inaugurated the ADC facility, which integrates
FDA reported that the facility is failing to perform adequate product testing and is practicing inadequate labelling or documentation of its drug products, The Globe And Mail reported.
The patent covers the synergistic effects of combination therapies containing COTI-2 and members of other classes of anti cancer agents. This patent provides extra protection for COTI-2 in
As per the agreement, Minophagen will have the exclusive rights to develop and commercialize the drug candidate. Eisai holds the right of first negotiation for the commercialization of